Richter Transformation: Testing New Combination Therapy

We are studying a combination of three medications for patients with Richter transformation of chronic lymphocytic leukemia. The goal is to evaluate how well this treatment works and its safety.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Tislelizumab
Tislelizumab is a cancer immunotherapy substance that helps the immune system attack tumor cells by blocking a protein called PD-1 that restrains immune responses.
Zanubrutinib
Zanubrutinib is a substance that treats certain B‑cell blood cancers by blocking a protein that helps cancerous B cells grow.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Bgb-11417
Benzamide

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University Of Vienna
University Hospital of Internal Medicine I, Clinical Division for Hematology and Hemostaseology
Vienna, Austria
Rigshospitalet
Department of Hematology
Copenhagen, Denmark
Technische Universitat Dresden
Med. Klinik und Poliklinik I
Dresden, Germany

Sponsor: University Of Cologne
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.